[en] OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. RESULTS: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial [CHEST-2]). CONCLUSION: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified.
Galiè, N., et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) International Society for Heart and Lung Transplantation (ISHLT). Eur. Respir. J. 46:4 (2015), 903–975.
Simonneau, G., et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 62:Suppl 25 (2013), D34–D41.
Kim, N.H., et al. Chronic thromboembolic pulmonary hypertension. J. Am. Coll. Cardiol. 62:25 Suppl (2013), D92–D99.
Fedullo, P., et al. Chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 183:12 (2011), 1605–1613.
Delcroix, M., et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur. Respir. J., 2020 in press.
Mayer, E., et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J. Thorac. Cardiovasc. Surg. 141:3 (2011), 702–710.
Jenkins, D., Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev. 24:136 (2015), 263–271.
Jenkins, D., et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev., 26(143), 2017.
Pepke-Zaba, J., et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124:18 (2011), 1973–1981.
Jenkins, D., et al. State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management. Eur. Respir. Rev. 21:123 (2012), 32–39.
Freed, D.H., et al. Survival after pulmonary thromboendarterectomy: effect of residual pulmonary hypertension. J. Thorac. Cardiovasc. Surg. 141:2 (2011), 383–387.
Mayer, E., Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev. 19:115 (2010), 64–67.
Hurdman, J., et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur. Respir. J. 39:4 (2012), 945–955.
Cannon, J.E., et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the UK national cohort. Circulation 133:18 (2016), 1761–1771.
Ghofrani, H.A., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 369:4 (2013), 319–329.
Simonneau, G., et al. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir. Med. 4:5 (2016), 372–380.
Kim, N.H., et al. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J., 53(1), 2019.
Hoeper, M., et al. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respir. J., 53(1), 2020 in press.
Simonneau, G., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur. Respir. J. 45:5 (2015), 1293–1302.
McLaughlin, V., et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulm. Med. 17:1 (2017), 216–224.
Bayer-AG. Adempas. Summary of Product Characteristics. European Medicines Agency website. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Product_Information/human/002737/WC500165034.pdf [cited 2019 May 22nd].
Bayer Pharma AG. US prescribing information: ADEMPAS (riociguat) tablets, for oral use. 2018 https://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf. (Accessed 14 January 2021)
Humbert, M., et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur. Respir. J. 36:3 (2010), 549–555.
Delcroix, M., et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 133 (2016), 859–871.
Kramm, T., et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin. Res. Cardiol. 107:7 (2018), 548–553.
Gall, H., et al. The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups. J. Heart Lung Transplant., 2017, S1053–S2498.
Trammell, A.W., et al. EXPRESS: mortality in U.S. veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factors. Pulm. Circ., 2019 2045894019825763.
Escribano-Subias, P., et al. Management and outcomes in chronic thromboembolic pulmonary hypertension: from expert centers to a nationwide perspective. Int. J. Cardiol. 203 (2016), 938–944.
Mueller-Mottet, S., et al. Long-term data from the Swiss pulmonary hypertension registry. Respiration 89:2 (2015), 127–140.
Condliffe, R., et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 177:10 (2008), 1122–1127.
Delcroix, M., et al. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. Eur. Respir. J., 52(5), 2018, 1800248.
McGoon, M.D., et al. Pulmonary arterial hypertension: epidemiology and registries. J. Am. Coll. Cardiol. 62:25 Suppl (2013), D51–D59.